medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2006, Number 3

<< Back Next >>

Rev Biomed 2006; 17 (3)

History of multiple myeloma

Díaz-Maqueo JC

Language: Spanish
References: 30
Page: 225-229
PDF size: 46.01 Kb.


ABSTRACT

Thanks to palepathology it has been found that multiple myeloma is an illness which has afflicted humanity since ancient times. The first two patients mentioned in modern literature were those described by Dr. Samuel Solly, who named the disease mollities ossium. Dr. Henry Bence Jones studied urine specimens provided by Drs. McIntyre and Watson, and described the now called Bence Jones (BJ) proteins. In 1873 Rustizky reported on another patient and used the term multiple myeloma for the first time to highlight the varying bone lesions that he found. In 1889 Otto Kahler published a revision about the illness, which came to be known as “Kahler’s disease”. However, Italians usually call it “Bozzolo’s disease”, in honor of their countryman Camillo Bozzolo (1845-1920). The first case published in the USA was that by Drs. Herrick and Hektoen in 1894. The term “plasmatic cells” was first used by the German pathologist Wilhelm von Waldeyer-Hartz (1836-1921). Nevertheless, there is a possibility that what he described were mast cells, and it was not until 1890 that Ramón y Cajal described them precisely. But it was James Homer Wright (1869-1928) who published till 1900 his discoveries in relation to plasmocytes, proving that they were malignant myeloma cells. In 1927 Arinkin pointed out the importance of bone marrow aspirates in the diagnosis of multiple myeloma and, later, in 1938, Rosenthal and Vogel confirmed this. A relation between BJ proteins and myeloma serum cells was demonstrated until 1956. Hyperglobulinemia was recognized by Perlzweig et al. in 1928. In 1939 Longsworth and coworkers used electrophoresis in the study of myeloma to prove the existence of a monoclonal peak. Cryoglobulinemia was recognized by Wintrobe and Buell in 1933, although the term was introduced by Lerner and Watson until 1947. In 1962 Bergsegel et al. informed that melfalan could induce remissions in approximately one third of the patients with myeloma.


REFERENCES

  1. 1.- Salmon SE, Cassady JR. Plasma cell neoplasms. En: DeVita VT Jr, Hellman S y Rosenberg SA, editores. Cancer. Principles and practice of oncology. 4th Edition. Volume 2. J. B. Lippincot Co. Philadelphia, Penn. 1993. pp 1986.

  2. 2.- Solly S. Remarks on the pathology of mollities ossium, with cases. Med Chir Trans 1844; 27:435-61.

  3. 3.- Kyle RA. Multiple Myeloma. An odyssey of discovery. British Journal of Haematology 2000; 111:1035–44.

  4. 4.- Bence Jones H. On a new substance occurring in the urine of a patient with mollities and fragilitas ossium. Phil Trans R Soc Lond 1848; 55:673.

  5. 5.- Dalrymple J. On the microscopical character of mollities ossium. Dublin Q J Med Sci 1846; 2:85.

  6. 6.- Rustizky J. Multiple myeloma. Deutsch Z Chir 1873;3:162-72.

  7. 7.- Kahler O. Zur Symptomatologie des multiplen myeloma: Beobachtung von albuminosurie. Prog Med Wochnschr 1889; 14:33-45.

  8. 8.- Brighetti A. Kahler-Bozzolo disease (Evolution of knowledge). Policlinico - Sezione Pratica May 22, 1967; 74(21):702-8.

  9. 9.- Herrick JB, Hektoen L. Myeloma: report of a case. Medical News 1894; 65:239–42.

  10. 10.- Weber EP, Hutchinson R, MacLeod JJR. Multiple myeloma (myelomatosis), with Bence–Jones protein in the urine: (myelopathic, albuminosuria of Bradsahw, Kahler’s disease). American Journal of Medical Science 1903; 126:644–65.

  11. 11.- Geschikter CF, Copeland MM. Multiple myeloma. Archives of Surgery 1928; 16:807–63.

  12. 12.- Bayrd ED, Heck EJ. Multiple myeloma: e review of eighty three proved cases. Journal of the American Medical Association 1947; 133:147–57.

  13. 13.- Waldeyer W. Ueber Bindegewebzellen. Archiv für Microbilogie und Anatomie 1875;11:176–94.

  14. 14.- Ramón y Cajal S. Estudios histológicos sobre los tumores epiteliales. Revista de Trimestr Microgr 1896; 1:83.

  15. 15.- Wright JH. A case of multiple myeloma. Transactions of the Association of American Physicians 1900; 15:137–47.

  16. 16.- Wright JH. A case of multiple myeloma. Johns Hopkins Hospital Report 1900; 9:359–66.

  17. 17.- Arinkin MI. Die intravitale Untersuchungsmethodik des Knochenmarks. Folia Haematologie 1929; 38:233–40.

  18. 18.- Rosenthal N, Vogel P. Value of the sternal puncture in the diagnosis of multiple myeloma. Journal of Mount Sinai Hospital 1938; 4:1001-19.

  19. 19.- Korngold L, Lipari R. Multiple-myeloma proteins. III. The antigenic relationship of Bence Jones proteins to normal gamma-globulin and multiple-myeloma serum proteins. Cancer 1956; 9:262–72.

  20. 20.- Perlzweig WA, Delrue G, Geschikter C. Hyperproteinemia associated with multiple myelomas: report of an unusual case. Journal of the American Medical Association 1928; 90:755–7.

  21. 21.- Longsworth LG, Shedlovshy T, Macinnes DA. Electrophoretic patterns of normal and pathological human blood serum and plasma. Journal of Experimental Medicine 1939; 70:399–413.

  22. 22.- Kunkel HG. The ‘abnormality’ of myeloma proteins. Cancer Research, 1968; 28:1351–3.

  23. 23.- Wintrobe MM, Buell MV. Hyperproteinemia associated with multiple myeloma, with report of a case in which an extraordinary hyperproteinemia was associated with thrombosis of the retinal veins and symptoms suggesting Raynaud’s disease. Bulletin of the Johns Hopkins Hospital 1933; 52:156–65.

  24. 24.- Lerner AB, Watson CJ. Studies of cryoglobulins. I. Unusual purpura associated with the presence of a high concentration of cryoglobulin (cold precipitable serum globulin). American Journal of Medical Sciences 1947; 214:410-5.

  25. 25.- Blokhin N, Larionov L, Perevodchikova N, Chebotareva L, Merkulova N. Clinical experiences with sarcolysin in neoplastic diseases. Annals of the New York Academy of Sciences 1958; 68:1128–32.

  26. 26.- Bergsagel DE, Griffith KM, Haut A, et al. Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma. IV: L-phenylalanine mustard (NSC-8806). Cancer Chemother Rep 1962; 21:87-99.

  27. 27.- Myeloma Trialists’ Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Journal of Clinical Oncology 1999; 16:3832–42.

  28. 28.- Avilés A, Díaz Maqueo JC, Guzmán R, García EL, Talavera A. Mieloma múltiple. Un análisis retrospectivo de 486 casos. Rev Med IMSS 1990; 28:137–41.

  29. 29.- Ruiz-Argüelles GJ. Gómez-Rangel JD. Ruiz-Delgado GJ. Aguilar-Romero L. Multiple myeloma in Mexico: a 20-year experience at a single institution. Archives of Medical Research 2004; 35:163-7.

  30. 30.- Sánchez-Medal L. The hemopoietic action of androstanes. Progress in Hematology 1971; 7:111-36.




2020     |     www.medigraphic.com